Vision
A future in which Lowe syndrome can be treated at its cause.
Mission
To develop treatments for Lowe syndrome and bring them to patients ourselves, rather than wait and hope that someone else will find it worth their time.
How we work
We start where families asked us to. Families told us to protect the kidneys first. That set our lead programme.
We build with the best. We run no laboratories of our own. We work with leading research institutions, among them TIGEM in Naples, Stanford University and Amsterdam UMC.
We use the right vehicle for each stage. The foundation carries the mission and the early research. Walther Therapeutics, the company the foundation owns, carries drug development.
We share what we learn. With families, clinicians and other rare disease organisations, and with the policymakers who decide how treatments for small patient groups are developed and approved.
Beyond Lowe syndrome
Dent disease type 2 is caused by the same gene, and our kidney programme is being developed for both. What we learn about treating one inherited kidney disease can shorten the road for the next.
See our research
Back to About us